NVCT

Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.

Nuvectis Pharma, Inc. (NVCT) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B); its weakest is Growth (D+).

Quantitative Factor Evaluation • Updated

Overall Rating
2.6 / 5.0
C+
Value
C+
Factor Score 2.5 / 5.0
Growth
D+
Factor Score 1.8 / 5.0
Profitability
C+
Factor Score 2.8 / 5.0
Momentum
B
Factor Score 3.3 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -21.1
EV / EBITDA N/A
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M 6.7%
Price Return 12M 233.8%
Catalyst Signal 0.00
Market Cap $695.7M
TTM Revenue N/A
Price / Sales N/A
ROE -67.0%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 C+ (2.5) D+ (1.8) C+ (2.8) B (3.3) C+ (2.6) C+ (2.6)
2026-11-06 C+ (2.5) D+ (1.8) C- (1.9) B (3.4) C+ (2.7) C (2.5)
2026-10-30 C+ (2.5) D+ (1.8) C (2.4) B (3.4) C+ (2.7) C+ (2.6)
2026-10-23 C+ (2.5) C- (1.9) C (2.4) B (3.4) C+ (2.6) C+ (2.6)
2026-10-16 C+ (2.5) D+ (1.8) C (2.4) B (3.4) C+ (2.6) C+ (2.6)
Page 1 of 3